States probe pharma markups as TMR policy faces scrutiny

State pharmaceutical regulators are intensifying scrutiny of price markups in the drug distribution chain, signalling a possible shift in how the government manages trade margins across India's pharmaceutical sector. Authorities in Maharashtra, Karnataka and Uttar Pradesh have begun systematic data collection on pricing practices, examining the spreads applied by wholesalers and retailers on medicines.

The coordinated effort among major pharmaceutical hubs suggests growing concerns about pricing transparency and potential anomalies in the current trade margin rationalisation (TMR) framework. The data gathered by state regulators could form the basis for a formal review of existing policies, which have long been contested by industry stakeholders and consumer advocates.

Trade margin rationalisation was introduced to standardise pharmaceutical distribution costs and prevent excessive markups at the retail level. However, implementation has remained inconsistent across states, with concerns that current guidelines may not adequately reflect market dynamics or address emerging pricing pressures.

The investigation comes amid broader regulatory attention on drug affordability and supply chain efficiency. State authorities aim to identify whether existing margin structures remain appropriate and whether policy adjustments are needed to balance industry viability with consumer access. The findings are expected to inform discussions with the central government on potential policy modifications.